ÂÜÀòÂÒÂ×

Dr. Carr serves as a Scientific Advisor to PrognomiQ. He is senior director of proteomics at the Broad Institute of MIT and Harvard, where he is also an institute scientist. He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology, chemistry, and medicine. His research has a major focus on the discovery and quantitative verification of biomarkers for major diseases including cancer and cardiovascular and infectious diseases, as well as pharmacodynamics markers of drug response. Prior to returning to academia in 2004, Dr. Carr held scientific leadership positions at GlaxoSmithKline where he was the director of computational and structural sciences and at Millennium Pharmaceuticals where he was senior director of protein science and technology. He has more than 350 publications, and he is deputy editor of Molecular and Cellular Proteomics, the leading journal in the field of proteomics. Dr. Carr received his B.S. from Union College and Ph.D. from MIT.